Q-Line Biotec
· SME · NSE
Price Band
₹326–343
Lot Size
400 shares
Issue Size
₹214 Cr
Min. Investment
₹1,37,200
Grey Market Premium
Indicative, updates through the day
Estimated listing price: ₹343
Subscription Status
Subscription data will appear once bidding opens.
About Q-Line Biotec
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company's key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices. As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines. As on March 31, 2026, the company had 362 permanent employees.
Issue Objectives
- To meet working capital requirements
- Repayment of certain borrowing availed by the Company, in part or full
- General Corporate Purposes
- Issue Expenses
Anchor Investors
Q-Line Biotec IPO raises ₹61.10 crore from anchor investors. Q-Line Biotec IPO Anchor bid date is May 20, 2026.
Reservation
| Category | Shares Offered | % |
|---|---|---|
| QIB | 29,69,200 | 49.99% |
| − Anchor Investor | 17,81,200 | 0% |
| − QIB (Ex. Anchor) | 11,88,000 | 0% |
| NII (HNI) | 8,91,600 | 15.01% |
| − bNII > ₹10L | 5,94,400 | 0% |
| − sNII < ₹10L | 2,97,200 | 0% |
| Retail | 20,79,200 | 35% |
| Market Maker | 3,13,200 | 0% |
- QIB50.0%
- − Anchor Investor0.0%
- − QIB (Ex. Anchor)0.0%
- NII (HNI)15.0%
- − bNII > ₹10L0.0%
- − sNII < ₹10L0.0%
- Retail35.0%
- Market Maker0.0%
Market Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 800 | ₹2,74,400 |
| Individual investors (IND) (Max) | 2 | 800 | ₹2,74,400 |
| S-HNI (Min) | 3 | 1200 | ₹4,11,600 |
| S-HNI (Max) | 7 | 2800 | ₹9,60,400 |
| B-HNI (Min) | 8 | 3200 | ₹10,97,600 |
Financials (₹ Cr)
Valuations
EPS (Pre IPO)
16.47
EPS (Post IPO)
22.12
ROE
16.88%
P/E (Pre IPO)
20.82
P/E (Post IPO)
15.51
Price / Book
2.44
Market Cap
₹800.16 Cr.
Peers Comparison
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Earkart Ltd. | 20.48 | ₹49.26 Cr | |
| Galaxy Medicare Ltd. | 19.01 | ₹22.31 Cr | |
| Fabtech Technologies Ltd. | 13.32 | ₹230.30 Cr |
Contact Details
Q-Line Biotech Ltd. Address
- +91 522-2435570
- compliance@qlinebiotech.com
- https://qlinebiotech.com/
Registrar Contact Details
Link Intime India Pvt. Ltd.
- +91 22 4918 6270
- ipo.helpdesk@linkintime.co.in
- https://linkintime.co.in
- C-101, 247 Park, LBS Marg, Vikhroli West, Mumbai – 400083
Frequently Asked Questions
Key Dates
- Open Date
- 21 May 2026
- Close Date
- 25 May 2026
- Listing Date
- 29 May 2026
Issue Details
- Registrar
- Link Intime India
- Lead Manager(s)
- Exchange
- NSE